Ascendis Pharma Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jan Mikkelsen
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 18.7yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 10yrs |
| Gemiddelde ambtstermijn bestuur | 7.8yrs |
Recente managementupdates
Recent updates
ASND: TransCon Platform Execution And Q2 Progress Should Drive Future Upside
Analysts have modestly raised their Ascendis Pharma price target to $313 from $305, citing fresh coverage and updated models that focus on the TransCon platform's three FDA approvals, Yorvipath's commercial ramp, Yuviwel's achondroplasia launch, and renewed interest in rare endocrine disease stocks. Analyst Commentary Recent Street research on Ascendis Pharma clusters around the company’s execution on its TransCon platform and the commercial progress of Yorvipath and Yuviwel.Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Ascendis Pharma A/S ( NASDAQ:ASND ) just released its latest second-quarter results and things are looking bullish. It...
ASND: Q2 Execution And M&A Interest Will Test Fairly Priced Story
Analysts have increased their price target for Ascendis Pharma, with the updated fair value estimate moving by about $11 to $259.95. This change reflects recent target hikes around Q2 earnings previews and a growing focus on the company's execution and potential M&A interest.ASND: Rare Endocrine Execution And Q2 Earnings Should Drive Future Upside
Analysts have lifted the Ascendis Pharma fair value estimate from $293.79 to $304.60, citing updated assumptions around revenue growth, profit margins, and sector-wide price target increases that reflect greater focus on company-specific execution. Analyst Commentary Recent Street research around Ascendis Pharma points to a generally constructive outlook on the stock, with several firms adjusting price targets higher and highlighting upcoming earnings as an important test of execution.ASND: M&A Hype And Launch Expectations Will Test Lofty Share Price
Analysts have nudged their fair value estimate for Ascendis Pharma lower from $254.97 to $248.54, reflecting updated assumptions around revenue growth, profit margins, and future P/E. The revision still coincides with higher Street price targets supported by recent research highlighting potential M&A interest and product launch traction.Ascendis Pharma: Behind The Stock Surge
Summary Ascendis Pharma has more than tripled over the past two and a half years, driven by Yorvipath's blockbuster launch and Yuviwel's FDA approval. Yorvipath's rapid adoption and ongoing label expansion underpin robust revenue growth. Yuviwel-Skytrofa combo therapy demonstrated unprecedented efficacy in achondroplasia, positioning ASND ahead of competitors pending pivotal trials. Patent litigation is one risk with the stock. An analysis around Ascendis Pharma follows in the paragraphs below. Read the full article on Seeking AlphaASND: Rare Endocrine Portfolio Progress Will Drive Future Upside Potential
The analyst price target for Ascendis Pharma has moved from $342.08 to $293.79 as analysts adjust their models to reflect updated assumptions on long term growth, margins and P/E expectations, alongside recent Street research that highlights confidence in Yorvipath and ongoing target revisions. Analyst Commentary Street research on Ascendis Pharma has recently centered on Yorvipath's commercial progress, updated growth assumptions and how these feed into valuation targets and execution risk.Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position
We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?CEO
Jan Mikkelsen (66 yo)
Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 18.7yrs | geen gegevens | geen gegevens | |
| CFO, Executive VP & Member of Executive Board | 10yrs | geen gegevens | 0.0066% $ 1.1m | |
| Executive VP | 18.7yrs | geen gegevens | 0% $ 0 | |
| Executive VP | 13.2yrs | geen gegevens | 0% $ 0 | |
| Senior VP | 2.5yrs | geen gegevens | 0% $ 0 | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Product Supply & Quality | 11yrs | geen gegevens | 0% $ 0 | |
| Executive VP and Head of Research & Product Development | 10.6yrs | geen gegevens | 0% $ 0 | |
| Head of U.S. Commercial of Endocrinology | 4.3yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | 1.9yrs | geen gegevens | 0% $ 0 | |
| Executive VP & President of Ascendis US | 1.6yrs | geen gegevens | 0% $ 0 | |
| Chief Regulatory & Safety Officer | 1.8yrs | geen gegevens | 0% $ 0 |
Ervaren management: Het managementteam van ASND is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 18.7yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | 0.0044% $ 735.2k | |
| Independent Chairman | 11.8yrs | €139.72k | 0% $ 0 | |
| Independent Director | 3.9yrs | €73.01k | 0% $ 0 | |
| Independent Director | 9.3yrs | €92.64k | 0% $ 0 | |
| Independent Director | 7.8yrs | €96.17k | 0% $ 0 | |
| Independent Director | 3.9yrs | €69.48k | 0% $ 0 |
Ervaren bestuur: De raad van bestuur van ASND wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/24 17:35 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ascendis Pharma A/S wordt gevolgd door 30 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Eliana Merle | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |